The FALCON trial: Impact of 18F-fluciclovine PET/CT on clinical management choices for men with biochemically recurrent prostate cancer.

Published on Feb 26, 2018in Journal of Clinical Oncology32.956
· DOI :10.1200/JCO.2018.36.6_SUPPL.165
Eugene J. Teoh11
Estimated H-index: 11
(University of Oxford),
David Bottomley20
Estimated H-index: 20
(Leeds Teaching Hospitals NHS Trust)
+ 15 AuthorsFergus V. Gleeson58
Estimated H-index: 58
(University of Oxford)
165Background: Detection of the extent of local recurrence and of metastases in biochemical recurrence (BCR) of prostate cancer facilitates selection of appropriate treatment. The FALCON trial (NCT02578940) assessed the impact of 18F-fluciclovine PET/CT on the clinical management of men with BCR of prostate cancer following initial radical therapy. Methods: Men being considered for curative-intent salvage therapy following first BCR were recruited at 6 UK sites. Management plans were documented prior to and following 18F-fluciclovine PET/CT imaging. Post-scan changes to treatment modality such as salvage radiotherapy [RT] to systemic therapy were classed as ‘major’, while changes within a modality (e.g. modified RT fields) were classed as ‘other’. A pre-planned interim analysis of the first 85 patients was conducted; recruitment was to be stopped for efficacy if the number of treatment changes was > 45 (52.9%; 97.5% CI: 40.3–62.3%), or for futility if ≤ 8 (9.4%, 97.5% CI: 3.6–18.9%). Results: The 85 enrol...
Cited By2
TO THE EDITOR: We read with great interest the article by Calais and colleagues, “Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence” ([1][1]). We consider it important that the data presented be interpreted appropriately. The
2 CitationsSource